At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 210 enrolled
Drug / intervention
Duloxetine +1 moredrug
Likely dose
Duloxetine 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Duloxetine Versus Placebo in the Treatment of Patients With Generalized Anxiety Disorder in China
In Brief
A Phase 3 clinical trial evaluating Duloxetine and Placebo for Generalized Anxiety Disorder. Completed, enrolled 210 participants across 7 sites.
Detailed Summary
This is a 15 week study comparing how well duloxetine and placebo treatments improve generalized anxiety disorder
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Anxiety Disorder
CountriesChina
CollaboratorsBoehringer Ingelheim
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
First PostedDec 2008
Primary CompletionJan 2010
TodayJul 2026
First PostedDec 5, 2008
Enrollment StartDec 1, 2008
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.6 years ago
Interventions
Duloxetinedrug
60 to 120 mg, capsules, oral, once a day for 15 weeks
Placebodrug
placebo capsules, oral, once a day for 15 weeks